874-39-5

Usage

Uses

Used in Public Health and Consumer Awareness:
7-Methylimidazo(1,2-a)pyridine is used as a reference compound for [raising awareness about the health risks associated with its presence in cooked and processed meats]. Efforts are focused on educating consumers and the food industry about the potential dangers of 7-MeI, encouraging the adoption of safer cooking methods and the reduction of its levels in meat products.
Used in Food Industry Research and Development:
7-Methylimidazo(1,2-a)pyridine is used as a target for [research aimed at developing methods to reduce its formation in cooked and processed meats]. This includes exploring alternative cooking techniques and ingredients that can minimize the production of 7-MeI while maintaining the quality and taste of meat products.
Used in Regulatory and Safety Assessments:
7-Methylimidazo(1,2-a)pyridine is used as a key indicator in [regulatory assessments and safety guidelines for cooked and processed meat products]. It helps in setting permissible levels and monitoring compliance to ensure that the exposure to this carcinogen is minimized, thereby reducing the associated health risks for consumers.

InChI:InChI=1/C8H8N2/c1-7-2-4-10-5-3-9-8(10)6-7/h2-6H,1H3

Upstream product

• 695-34-1 2-Amino-4-methylpyridine 
• 107-20-0 2-chloroethanal 
• 2032-35-1 Bromoacetaldehyde diethyl acetal 
• 17157-48-1 bromoacetaldehyde 

Downstream Products

• 144042-81-9 7-Methyl-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine 
• 30384-94-2 7-methylimidazo<1,2-a>pyridine-3-carboxaldehyde 
• 91427-49-5 2-(2-chloroethoxy)ethyl benzoate 
• 59938-33-9 3-iodo-7-methylimidazo[1,2-a]pyridine 
• 882187-78-2 7-methyl-3-phenylimidazo[1,2-α]pyridine 

Relevant academic research and scientific papers

From Synthetic Simplified Marine Metabolite Analogues to New Selective Allosteric Inhibitor of Aurora B Kinase

Significant inhibition of Aurora B was achieved by the synthesis of simplified fragments of benzosceptrins and oroidin belonging to the marine pyrrole-2-aminoimidazoles metabolites isolated from sponges. Evaluation of kinase inhibition enabled the discovery of a synthetically accessible rigid acetylenic structural analogue EL-228 (1), whose structure could be optimized into the potent CJ2-150 (37). Here we present the synthesis of new inhibitors of Aurora B kinase, which is an important target for cancer therapy through mitosis regulation. The biologically oriented synthesis yielded several nanomolar inhibitors. The optimized compound CJ2-150 (37) showed a non-ATP competitive allosteric mode of action in a mixed-type inhibition for Aurora B kinase. Molecular docking identified a probable binding mode in the allosteric site "F"and highlighted the key interactions with the protein. We describe the improvement of the inhibitory potency and specificity of the novel scaffold as well as the characterization of the mechanism of action.

Pd-Catalyzed Tandem Cyclization via C-H Arylation and Acylation for the Construction of Polycyclic Scaffolds

The first Pd-catalyzed tandem cyclization of imidazo[1,2-a]pyridines with 2-chlorobenzaldehydes through C-H arylation and acylation is presented for the efficient synthesis of novel 6H-benzo[b]imidazo[5,1,2-de]quinolizin-6-ones. The direct acylation react

NEW COMPOUNDS

The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease

The invention provides compounds of Formula I: 1These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat conditions or diseases in which α7 is known to be involved.

Substituent effects on fluorescent properties of imidazo[1,2- α]pyridine-based compounds

In order to search for novel fluorescent organic compounds, 20 derivatives of imidazo[1,2-a]pyridine (1) were synthesized, and their fluorescent properties were studied. Though the parent compound I (λ(fl) = 370.5 nm, Φ = 0.57 in ethanol) was in the liquid state at ambient temperature, 2-phenylimidazo[1,2-a]pyridine (5), 2-(2-naphthyl)imidazo[1,2- a]pyridine (16), 7-methylimidazo[1,2-a]pyridine (3), 7-methyl-2- phenylimidazo[1,2-a]pyridine (12), and 7-methyl-2(2-naphthyl)imidazo[1,2- a]pyridine (17) were found to give thermally stable solid compounds (mp 55- 190 °C) without much affecting the fluorescent properties of the parent compound (λ(fl) = 374-381 nm, Φ = 0.50-0.78 in ethanol). Among the 4'- substituted 2-phenyl derivatives, it was found that the introduction of the strong electron-donating amino and dimethylamino groups (2-(4- aminophenyl)imidazo[1,2-a]pyridine (7) and 2-[4- (dimethylamino)phenyl]imidazo[1,2-a]pyridine (8), respectively) caused marked red shift of their fluorescence (λ(fl) = 445 and 446 nm, respectively, in ethanol), thus providing the way for tuning the fluorescence color of the IP derivatives. The observed red shift of the fluorescence of 7 and 8 was ascribed to the contribution of the excited intramolecular charge transfer state.

Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents

The synthesis and the antiviral activities of C-3 acyclic nucleoside analogues of imidazo[1,2-a]pyridine and pyrimidine are reported. From these compounds, 20, 21, 22, 23, 28, and 34 showed a specific activity against cytomegalovirus and/or varicella-zoster virus.

Synthesis and antimuscarinic properties of some N-substituted 5- (aminomethyl)-3,3-diphenyl-2(3H)-furanones

In a study aimed toward developing new, selective antimuscarinic drugs with potential utility in the treatment of urinary incontinence associated with bladder muscle instability, a series of N-substituted 5-(aminomethyl)- 3,3-diphenyl-2(3H)-furanones, conformationally-constrained lactone relatives of benactyzine, was prepared. The compounds were examined in several paradigms that measure muscarinic (M1, M2, and M3) receptor antagonist activity. Selected members of the series that displayed potency and/or selectivity in these tests were studied for their effects on urinary bladder contraction, mydriasis, and salivation in guinea pigs. These studies revealed that incorporation of the amino functionality into an imidazole or pyrazole ring resulted in some novel, potent, and selective antimuscarinic agents. Appropriate alkyl substitution of position 2 of the imidazole strikingly affected muscarinic, particularly M3, receptor activity and may reflect a complementary site of interaction. Some of the compounds selectively reduced bladder pressure in a cystometrogram (CMG) model without producing concomitant mydriatic and salivary effects. The separate and distinct action of several compounds of this series in these in vivo protocols suggests the possibility of subtypes of muscarinic receptors that may correspond to previously characterized molecular cloned subpopulations. In this article, structure-activity relationships for the series of substituted lactones are discussed. These studies led to the identification of (R)-[(2-isopropyl-1H- imidazol-1-yl)methyl]-4,5-dihydro-3,3-diphenyl-2(3H)-furanone (23) as a clinical candidate for treating urinary bladder dysfunction.